Watch now on PsychU: [ Ссылка ]
PsychU Section Advisor, Dr. René Kahn takes a moment to share his insights into the state of treatment and advances in research on schizophrenia. He touches on clinical trials on antipsychotics; the importance of early intervention; recent advances in genetic findings related to schizophrenia; and progress on the understanding of cognition in patients living with this condition.
René Kahn, MD, PhD, is a PsychU Schizophrenia Section Advisor. In addition, he serves as the Esther & Joseph Klingenstein Professor & System Chair of Psychiatry at the Icahn School of Medicine at Mount Sinai. He has published over 800 research papers, and in 2015 and 2016 was named Thomson Reuters’ highly cited researcher, and award representing ‘some of the world’s most influential scientific minds.’
#MentalHealth #Schizophrenia #TreatingSchizophrenia #BehavioralHealth #EarlyIntervention #genetics
Speaker was a paid consultant to Otsuka Pharmaceutical Development & Commercialization, Inc.
PsychU is supported by Otsuka Pharmaceutical Development & Commercialization, Inc. (OPDC), Otsuka America Pharmaceutical, Inc. (OAPI), and Lundbeck, LLC – committed supporters of the mental health treatment community. The opinions expressed by PsychU’s contributors are their own and are not endorsed or recommended by PsychU or its sponsors. The information provided through PsychU is intended for the educational benefit of mental health care professionals and others who support mental health care. It is not intended as, nor is it a substitute for, medical care, advice, or professional diagnosis. Health care professionals should use their independent medical judgement when reviewing PsychU's educational resources. Users seeking medical advice should consult with a health care professional. No CME or CEU credits are available through any of the resources provided by PsychU. Some of the contributors may be paid consultants for OPDC, OAPI, and / or Lundbeck, LLC.
Watch now on PsychU: [ Ссылка ]
MRC2.CORP.X.03366
